# Cyclophosphamide

## Endoxan inj 500mg

| TAH Drug Code      | [IEND5](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=IEND5)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|:-------------------|:------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Treatment for lymphatic leukemia, disseminated tumors, chronic lymphatic leukemia, lymphosarcoma, various reticuloendotheliosis, and to prevent tumor relapse.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Dosing             | Maintenance therapy: IV 3-6mg/kg/day (equivalent to 120-240mg/m2 of BSA). Intermittent therapy: 10-15mg/kg (equivalent to 400-600mg/m2 of BSA), followed by intervals of 2-5 days. High-dose intermittent therapy: 20-40mg/kg (equivalent to 800-1600mg/m2 of BSA) or higher doses, especially in the case of bone marrow transplantation, with intervals of 21-28 days.                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Hepatic Impairment | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Renal Impairment   | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Contraindications  | Allergic to cyclophosphamide. Severe bone marrow dysfunction, especially in patients previously treated with cytotoxic agents or radiation therapy. Cystitis. Urethral blockage. Active infections. Pregnancy and lactation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Adverse Effects    | Common: Alopecia, Disorder of skin pigmentation, Injury of nail, Rash, Abdominal discomfort, Diarrhea, Loss of appetite, Nausea and vomiting, Leukopenia, Neutropenia, Amenorrhea Serious: Cardiac tamponade, Cardiotoxicity, Congestive heart failure, Pericardial effusion, Erythema multiforme, Malignant tumor of dermis, Stevens-Johnson syndrome, Toxic epidermal necrolysis, Acute myeloid leukemia, Chronic myeloid leukemia, Malignant tumor of lymphoid hemopoietic and related tissue, Myelodysplastic syndrome, Angiosarcoma of liver, Anaphylaxis, Acquired contracture of bladder neck, Bladder cancer, Fibrosis of urinary bladder, Hemorrhagic cystitis, Metastatic malignant neoplasm to renal pelvis, Pyelitis, Renal hematuria, Azoospermia, Oligozoospermia, Interstitial pneumonia, Pulmonary fibrosis, Infectious disease |
| Pregnancy          | No Data                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Lactation          | No Data                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |

## Endoxan 50mg

| TAH Drug Code      | [OEND](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=OEND)                                                                                                                                                                                                                                                                                           |
|:-------------------|:---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Treatment of acute lymphoblastic leukemia (ALL), acute myelocytic leukemia (AML), breast cancer, chronic lymphocytic leukemia (CLL), chronic myeloid leukemia (CML), Hodgkin lymphoma, mycosis fungoides, multiple myeloma, neuroblastoma, non-Hodgkin lymphomas (including Burkitt lymphoma), ovarian adenocarcinoma, retinoblastoma, and nephrotic syndrome. |
| Dosing             | For continuous therapy 1-4 tablets (50-200 mg) daily; if necessary, more tablets may be taken. The dose recommendations given mainly apply to the treatment with cyclophosphamide as a monotherapy. In combination with other cytostatics of similar toxicity, a dose reduction or extension of the therapy-free intervals may be necessary.                   |
| Hepatic Impairment | Dose adjustment required                                                                                                                                                                                                                                                                                                                                       |
| Renal Impairment   | Dose adjustment required                                                                                                                                                                                                                                                                                                                                       |
| Contraindications  | Hypersensitivity to cyclophosphamide or its metabolites, urinary outflow obstructions, severe myelosuppression, severe renal or hepatic impairment, active infection (especially varicella zoster), severe immunosuppression.                                                                                                                                  |
| Adverse Effects    | Nausea, vomiting; bone marrow depression, leukopenia; alopecia; mucosal ulceration; pigmentation; interstitial pulmonary fibrosis; fluid retention                                                                                                                                                                                                             |
| Pregnancy          | Contraindicated – 1st Trimester                                                                                                                                                                                                                                                                                                                                |
| Lactation          | Contraindicated                                                                                                                                                                                                                                                                                                                                                |

